Navigating biochemical research requires analytical certainty, particularly when investigating novel mitochondrial-derived peptides. Independent third-party testing guarantees that experimental compounds meet stringent purity, identity, and safety metrics prior to laboratory deployment.
Navigating biochemical research requires analytical certainty, particularly when investigating novel mitochondrial-derived peptides. Independent third-party testing guarantees that experimental compounds meet stringent purity, identity, and safety metrics prior to laboratory deployment.
A third-party tested MOTS-c sample has undergone independent, non-affiliated laboratory analysis using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity determination, Electrospray Ionization Mass Spectrometry (ESI-MS) for sequence identification, and Limulus Amebocyte Lysate (LAL) testing for endotoxin quantification.
To qualify for rigorous laboratory research, third-party certification must confirm an analytical purity exceeding 98%, accurate molecular weight verification matching the 16-amino-acid peptide sequence, and endotoxin levels below 0.5 EU/mg to prevent confounding immunological signaling during assays.
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome rather than the nuclear DNA. Identified as part of a emerging class of mitochondrial-derived peptides (MDPs), MOTS-c functions as a signaling molecule involved in cellular stress adaptation and systemic homeostatic control.
In vitro data indicate that MOTS-c translocates to the nucleus under conditions of metabolic stress, where it interacts with specific nuclear transcription factors to modulate nuclear gene expression. Researchers examining cellular respirometry frequently utilize our high-purity MOTS-c peptide to evaluate its role in bioenergetics without the interference of residual synthesis artifacts.
Preclinical studies suggest that MOTS-c plays an active role in metabolic regulation, specifically through the activation of the 5'-AMP-activated protein kinase (AMPK) pathway. In rodent models of metabolic dysregulation, administration of MOTS-c has demonstrated enhanced glucose clearance, increased fatty acid oxidation, and improved insulin sensitivity across skeletal muscle tissue.
Further research highlights the peptide's capacity to maintain mitochondrial function during stress. Animal models subjected to high-fat dietary interventions or physical exercise challenges demonstrate altered endogenous MOTS-c expression. Additional details regarding structural characteristics and biochemical pathways are documented within our comprehensive MOTS-c mechanism guide.
Solid-phase peptide synthesis (SPPS) for a 16-residue chain like MOTS-c inevitably generates unwanted side products, including truncated sequences, deleted residues, and residual trifluoroacetic acid (TFA) salts. Without independent analytical verification, researchers risk introducing impure reagents into assays, leading to skewed experimental baseline measurements or non-reproducible cellular toxicity.
Independent verification ensures that every batch ordered from a reliable source like the PX1 Research catalog conforms strictly to declared physical and chemical specifications. A comprehensive Certificate of Analysis (COA) provides researchers with traceable data directly tied to specific production lots.
Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) serves as the industry standard for determining chemical purity. By passing the peptide through a hydrophobic stationary phase under high pressure, RP-HPLC separates the target MOTS-c molecule from truncated analogs and chemical impurities, establishing a percentage of purity based on peak area integration.
Mass Spectrometry (MS)—specifically liquid chromatography-mass spectrometry (LC-MS) or matrix-assisted laser desorption/ionization (MALDI)—verifies the precise mass-to-charge ratio of the compound. The theoretical molecular weight of MOTS-c (2174.6 Da) must align precisely with the observed mass spectrum to confirm sequence fidelity.
Bacterial endotoxins (lipopolysaccharides) represent a major contamination risk in synthetic peptide production. Even minute quantities of endotoxin can trigger inflammatory cascades in macrophage cell lines or induce septic responses in animal models, invalidating experimental outcomes regarding metabolic or mitochondrial behavior.
PX1 Research enforces strict endotoxin screening protocols utilizing chromogenic LAL assays. For in vitro and in vivo laboratory research use only, MOTS-c lots must yield endotoxin levels well below established safety thresholds (<0.5 EU/mg), ensuring that cellular responses are directly attributable to the peptide mechanism rather than immunogenic contaminants.
When evaluating compounds for metabolic regulation and mitochondrial health, researchers often compare MOTS-c with other targeted signaling agents. While MOTS-c acts via nuclear translocation and AMPK activation, the cardiolipin-targeting tetrapeptide SS-31 functions primarily by stabilizing mitochondrial inner membrane structure and reducing reactive oxygen species (ROS) production, as outlined in our SS-31 research breakdown.
Similarly, small molecule inhibitors such as 5-Amino-1MQ target metabolic flux through NNMT inhibition rather than peptide-mediated receptor signaling. Selecting the appropriate compound requires matching the analytical profile of the reagent to the specific cellular pathway under investigation.
Proper handling is critical to maintaining the structural integrity of third-party verified MOTS-c upon delivery. Lyophilized MOTS-c should be stored at -20°C or -80°C in a dry environment protected from light. Prior to opening, vials must be allowed to equilibrate to room temperature to prevent condensation accumulation on the peptide cake.
Reconstitution should be performed using sterile, laboratory-grade solvents such as bacteriostatic water or sterile phosphate-buffered saline (PBS), depending on the experimental application. Once reconstituted, solution aliquots should be frozen immediately to avoid repeated freeze-thaw cycles, which induce mechanical shear and enzymatic degradation. For institutional ordering and bulk research needs, explore our wholesale account options.
PX1 Research manufactures peptides in ISO 17025 accredited and cGMP-compliant facilities located in the USA. By maintaining domestic production oversight, we ensure stringent quality assurance at every stage of synthesis, purification, and packaging.
Every batch of MOTS-c is subjected to rigorous lot-by-lot testing. We publish comprehensive certificates containing raw HPLC chromatograms, mass spectra, and endotoxin assay results within our central research documentation hub. This transparent framework gives investigators complete confidence in reagent purity and experimental reproducibility.
What analytical tests confirm that MOTS-c is third-party tested?
Third-party verification of MOTS-c requires Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity quantification, Mass Spectrometry (MS) for molecular weight identification, and a Limulus Amebocyte Lysate (LAL) assay for endotoxin quantification.
Why is third-party testing necessary for MOTS-c research?
Peptide synthesis can introduce truncated sequences, residual solvents, and endotoxins. Third-party testing verifies that the MOTS-c reagent is free of baseline-disrupting contaminants, ensuring reproducible experimental data.
What is the purity standard for PX1 Research MOTS-c?
All MOTS-c lots supplied by PX1 Research are verified via RP-HPLC to meet or exceed 98% chemical purity.
How should lyophilized MOTS-c be stored upon arrival?
Lyophilized MOTS-c should be stored at -20°C or -80°C in a desiccated, dark environment to preserve peptide stability prior to reconstitution.
What endotoxin limit is acceptable for MOTS-c in preclinical research?
PX1 Research requires endotoxin levels to remain below 0.5 EU/mg (and frequently below 0.1 EU/mg) to prevent unwanted inflammatory responses in cellular assays or animal models.
How does MOTS-c differ from the mitochondrial peptide SS-31?
MOTS-c is a 16-amino-acid mitochondrial-derived peptide that translocates to the nucleus to regulate metabolic gene expression and AMPK pathways. SS-31 is a synthetic tetrapeptide that binds to cardiolipin in the inner mitochondrial membrane to optimize electron transport and reduce oxidative stress.
Can reconstituted MOTS-c be repeatedly frozen and thawed?
No. Repeated freeze-thaw cycles degrade peptide bonds and cause aggregation. Reconstituted MOTS-c should be divided into single-use aliquots and stored at -20°C or -80°C.
Where can researchers obtain the COA for a specific lot of MOTS-c?
Lot-specific Certificates of Analysis including HPLC chromatograms and mass spectra are accessible directly through the PX1 Research online platform or upon request from our quality assurance team.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.